MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.
about
Reducing the probability of false positive research findings by pre-publication validation - experience with a large multiple sclerosis databaseMR spectroscopy indicates diffuse multiple sclerosis activity during remissionTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Clinical correlates of grey matter pathology in multiple sclerosisReduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 TeslaA combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology.Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.Pooled historical MRI data as a basis for research in multiple sclerosis--a statistical evaluation.MRI in multiple sclerosis: what's inside the toolbox?Multiple sclerosis lesions: insights from imaging techniques.Global N-acetylaspartate declines even in benign multiple sclerosisEvidence for a two-stage disability progression in multiple sclerosisClinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques.T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis.Gradient echo magnetic resonance imaging correlates with clinical measures and allows visualization of veins within multiple sclerosis lesionsMultiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model.Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis.Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis.Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyLower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T.Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: a surface-based analysis.Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.Natural history of multiple sclerosis symptomsMR imaging in multiple sclerosis: review and recommendations for current practice.Gender issues in multiple sclerosis: an update.Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Serum retinol levels are associated with brain volume loss in patients with multiple sclerosis.A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliabilityThe impact of isolated lesions on white-matter fiber tracts in multiple sclerosis patientsMeasuring the quality of life in patients with multiple sclerosis in clinical practice: a necessary challenge.Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis.Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis.Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis.
P2860
Q24288959-5E65F39F-3F7D-4960-BFF0-65446B297A04Q24615946-B92C0363-9955-474E-80D9-771F7C935938Q26798434-D60FBA9E-997A-483F-BAF9-50F40564DAD3Q26999302-A6B9A6CC-96F7-42B4-A0BD-D82E55FC042BQ28474867-CC6D4A6E-1D77-4F1D-900A-20E71F3C82DEQ30525646-E9A14933-8BDE-46B8-B5A5-7C8E53C6C241Q30581773-8E2CEA5F-41F8-465F-9D94-2729D5315A97Q31110608-222AE677-462D-4BE4-A567-32EBECC39495Q31132442-3D4DEB81-2AB6-4258-8B3E-3269A057B179Q33505423-15C54513-7111-4DB5-82E9-078672B97A18Q33725131-92AEEB3B-2EB6-40CF-9A68-D402208E345DQ33944184-03C4FA56-D91D-4455-88F7-087F46B9F189Q34171891-066E0383-2DF2-4C18-927D-3C6479C86DF8Q34410090-E75F8BE4-3C26-4B92-BE94-63245A00F2A2Q35198492-471B156C-963A-4D72-886B-E5A5F7C39BFCQ35683398-985802A8-B0A7-4CEC-9A16-F3A2CDD753BBQ35938583-9DFCF968-932E-42F3-92C1-650F2B0B5FBDQ36035077-341565F3-4D94-4EC7-8616-310FA9B572F5Q36731484-68B63518-1A02-4B1F-83F1-251040DBEFECQ37059931-A2A84A4A-D7E8-477C-8743-0CEFA561A4A4Q37142971-1AF44D48-64CF-437D-8A9D-0DFF02A41749Q37296089-AF1FDB6F-D998-4E78-92CB-B21730D8314BQ37388176-E4959CA6-55AA-4927-A925-D78DBD21C487Q37442391-A1CD51E2-A034-4736-8184-3380B163140EQ37658010-B36DB3DA-3A1E-4011-9F37-F18B55134649Q37813691-3A6C92CD-C24E-4E26-B23A-D2E72123BECDQ37969082-4578CBD5-1198-439B-88FA-E65CDD3C0F02Q38375605-C04E205E-3942-4FF9-B7FA-A20857C8CA18Q38625426-087987D3-8E09-47D9-AA85-27E6C0C51E89Q38910574-0A16EA95-FFD7-46EE-8232-1838DBBBF20CQ41078810-DE3DFF43-EB2D-43F4-B22D-977DC58E170CQ41369774-9853A2F7-44DE-481E-BCAF-3B4ADF59715FQ41613266-A9E078F2-36EA-4A1D-AE85-9665876591C2Q41868004-175653CF-8818-4AD7-8A74-AF5437C9AFB4Q43004069-EA031E2B-CF84-4118-A574-8C45B1008CC6Q43416448-113FF128-C4B7-4825-9D85-8E4C50ACB16FQ43606941-ACE824F4-5C40-43A4-B44E-10E61A4F8C96Q44787272-3C2FA6E9-3BAB-477B-AD79-403FAA845BC4Q45238890-D9241FCB-243E-4170-ABC8-9086696236BDQ45344837-D2A1C781-327E-4BB8-A645-6B390F12812A
P2860
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
MRI T2 lesion burden in multip ...... ship with clinical disability.
@en
MRI T2 lesion burden in multip ...... ship with clinical disability.
@nl
type
label
MRI T2 lesion burden in multip ...... ship with clinical disability.
@en
MRI T2 lesion burden in multip ...... ship with clinical disability.
@nl
prefLabel
MRI T2 lesion burden in multip ...... ship with clinical disability.
@en
MRI T2 lesion burden in multip ...... ship with clinical disability.
@nl
P2093
P1433
P1476
MRI T2 lesion burden in multip ...... ship with clinical disability.
@en
P2093
D H Miller
J S Wolinsky
P304
P356
10.1212/01.WNL.0000210506.00078.5C
P407
P577
2006-05-01T00:00:00Z